1. A New Paradigm for Early Diagnosis and Surveillance
For Liver Cancer
Lawrence Cohen, CEO
77 Water Street , Suite 817
New York, NY 10005

2. Series A Financing Closed
Fosun Pharma and NetScientific plc investors
$10MM equity investment
$3MM on close
$7MM on completion of certain milestones
Subject to Chinese ODI and US CFIUS approval
Fosun receives:
40% equity stake in Glycotest
Exclusive license for China to the Glycotest HCC Panel early-stage liver cancer test
Glycotest earns royalty on sales in China
Glycotest will use proceeds to:
Launch the HCC Panel in the US
Transfer HCC Panel technology to Fosun
Further develop pipeline tests for liver fibrosis and cholangiocarcinoma

3. Glycotest
The Company
Founded 2012 on technology innovated at the Baruch S. Blumberg Institute and Drexel University College of Medicine (Philadelphia)
Glycotest technology has benefitted from $8.9MM in grants to the innovators
Proprietary blood-based biomarkers, panels and algorithms for the surveillance of patients at high risk of serious liver disease
Five US and eight ex-US patents issued or allowed covering >50 novel glycoprotein biomarkers; additional patents pending
Focused on liver cancer and fibrosis surveillance
Commercial clinical laboratory services for patients at risk for liver cancers and fibrosis
>$1B opportunity—huge and growing populations with viral and non-viral hepatitis driving progressive fibrosis and liver cancer risk
Lead product—biomarker panel for hepatocellular carcinoma (HCC Panel) to surveil patients at risk for predominant form of primary liver cancer

4. > $1B HCC Panel Market Opportunity
Huge and growing populations with viral and non-viral hepatitis—driving progressive fibrosis, liver cancer risk and need for effective disease surveillance
Chronic hepatitis B: 2.2 MM US; 360 MM WW; incurable
Chronic hepatitis C: 3.2 MM US; 170 MM WW; liver cancer risk persists despite cure
Fatty liver disease and NASH / ASH: >100 MM US; >1.5 B WW; rapidly growing populations due to obesity and metabolic disease
Cirrhosis: 3.2 MM US; 73 MM WW; secondary to hepatitis; proximate cause of most liver cancer
Estimated market value for the HCC Panel is $818 MM in the US alone
Assumes only 620,000 US patients under surveillance—20% of 3.1 MM eligible patients
In China…
> 350,000 people die of liver cancer each year
> 350MM people at risk for liver cancer due to serious liver disease—viral hepatitis, fatty liver disease and NASH, alcoholic liver disease and ASH
Liver cancer surveillance drives lower healthcare costs
Early detection of HCC enables lower cost curative therapy—resection or ablation
Later stage HCC is only eligible for higher cost palliative therapy—TACE or chemotherapy
Cost effective HCC panel will enable early-stage HCC detection, lower cost treatment options, and better patient outcomes that will drive market adoption

5. Lead Product—HCC Panel
Algorithm-driven panel—surveillance for curable HCC
To detect curable early-stage disease
To provide a convenient blood test that guides CT / MRI confirmation
For patients at risk due to both viral and non-viral hepatitis
Early-stage HCC is curable
Resection and ablation lead to long-term disease free survival
Curative treatment is less costly than palliative care for later stage disease
Current blood tests and imaging modalities have low sensitivity and/or specificity—curable early-stage disease is being missed
Large and expanding population needs an effective HCC surveillance solution
Cirrhosis + chronic hepatitis B w/o cirrhosis—3.1 MM US; 323 MM WW
NASH pandemic expanding market
Chronic testing opportunity—repeat testing every 3-6 months
Glycotest’s HCC Panel significantly outperforms currently dominant blood test (AFP) in three clinical studies involving >480 patients

6. HCC Panel Technology and Clinical Performance
Glycotest’s proprietary HCC Panel relies on novel glycoprotein biomarkers
Unique abnormal change in sugar structure in liver disease— core fucose disease signal
Data from three head-to-head clinical studies in >480 patients demonstrate performance superior to AFP, the currently dominant blood test for HCC surveillance